Daily Archives: May 1, 2023

Very early onset inflammatory bowel disease (VEOIBD) is defined as disease onset prior to age 6. VEOIBD is monogenic in >5% of cases; however, in the remaining cases, molecular basis of disease is unknown. We aimed to utilize bulk RNA-seq of blood to 1… Continue reading →

Several risk factors have been associated with inflammatory bowel diseases (IBD), including genetic, environmental, gut microbiota and immune dysregulation. Psychiatric disorders have been linked to IBD. However, the question of whether psychiatric con… Continue reading →

Inflammatory bowel disease (IBD) is well known for concurrent immune-mediated disorders such as eosinophilic esophagitis, psoriasis, and rheumatoid arthritis. (1) For the past two decades, we are seeing an increased occurrence of eosinophilic esophagit… Continue reading →

Restorative proctocolectomy with ileal pouch anal anastomosis (IPAA) removes the entire rectum to the anal canal, but is technically challenging, especially with minimally invasive (MIS) approaches. Pouches are most commonly double-stapled, leaving a 1… Continue reading →

Motility dysfunction is present in patients with stenotic Crohn’s disease (CD) and contributes to cramps, diarrhea and constipation. However, mechanisms for motility dysfunction in CD are incompletely understood. Mechanical stress, i.e. inflammatory in… Continue reading →

There is limited and conflicting data available regarding the Cardiovascular disease outcomes associated with Inflammatory Bowel Disease (IBD) Continue reading →

Comparative efficacy of biologics is an important consideration when selecting therapies for Crohn’s disease (CD). While recent studies have focused on clinical remission, few studies have assessed the comparative efficacy of biologics in preventing pe… Continue reading →

Clinical guidelines recommend the incorporation of risk stratification assessments when making decisions about Crohn’s disease (CD) treatment. We aimed to evaluate if patient and gastroenterologist (GI) decision making and confidence about starting or … Continue reading →

Inflammatory bowel disease (IBD) causes T cell infiltration of the intestinal mucosa, but the heterogeneity of these cells is not understood at a clonal level. The drug vedolizumab is believed to treat IBD by blocking the entry of circulating integrin … Continue reading →

Patients with inflammatory bowel disease (IBD) are at increased risk of colorectal cancer. In cases of invisible or non-endoscopically resectable dysplasia found at colonoscopy, total proctocolectomy with ileal pouch anal anastomosis can be offered wit… Continue reading →